Beaufort Securities upgraded shares of GlaxoSmithKline (LON:GSK) to a buy rating in a report released on Thursday morning. They currently have GBX 1,500 ($21.03) target price on the stock, up from their prior target price of GBX 1,450 ($20.33).
A number of other analysts have also commented on the company. Societe Generale reissued a sell rating on shares of GlaxoSmithKline in a report on Thursday, November 9th. Berenberg Bank reduced their target price on GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a buy rating for the company in a report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($20.33) target price on GlaxoSmithKline and gave the company a sell rating in a report on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($22.57) target price on GlaxoSmithKline and gave the company a neutral rating in a report on Friday, October 27th. Finally, Barclays reaffirmed an equal weight rating and issued a GBX 1,450 ($20.33) target price on shares of GlaxoSmithKline in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of Hold and an average target price of GBX 1,541.36 ($21.61).
Shares of GlaxoSmithKline (LON GSK) traded down GBX 15.40 ($0.22) on Thursday, reaching GBX 1,288.40 ($18.07). The company’s stock had a trading volume of 8,051,208 shares, compared to its average volume of 9,220,000. The company has a market cap of $64,140.00 and a price-to-earnings ratio of 4,156.13. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.32) and a 1 year high of GBX 1,724.50 ($24.18).
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.